{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:18:56Z","timestamp":1790957936015,"version":"4.1.0"},"reference-count":214,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["MH081917"],"award-info":[{"award-number":["MH081917"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["AG056815"],"award-info":[{"award-number":["AG056815"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["AG064664"],"award-info":[{"award-number":["AG064664"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["AG062655"],"award-info":[{"award-number":["AG062655"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["SAGA23-1142437"],"award-info":[{"award-number":["SAGA23-1142437"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["GeroScience"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Alzheimer\u2019s disease (AD) is a devastating neurodegenerative disorder characterized by relentless cognitive decline and the emergence of profoundly disruptive neuropsychiatric symptoms. As the disease progresses, it unveils a formidable array of neuropsychiatric manifestations, including debilitating depression, anxiety, agitation, and distressing episodes of psychosis. The intricate web of the monoaminergic system, governed by serotonin, dopamine, and norepinephrine, significantly influences our mood, cognition, and behavior. Emerging evidence suggests that dysregulation and degeneration of this system occur early in AD, leading to notable alterations in these critical neurotransmitters\u2019 levels, metabolism, and receptor function. However, how the degeneration of monoaminergic neurons and subsequent compensatory changes contribute to the presentation of neuropsychiatric symptoms observed in Alzheimer\u2019s disease remains elusive. This review synthesizes current findings on monoamine alterations in AD and explores how these changes contribute to the neuropsychiatric symptomatology of the disease. By elucidating the biological underpinnings of AD-related psychiatric symptoms, we aim to underscore the complexity and inform innovative approaches for treating neuropsychiatric symptoms in AD.<\/jats:p>\n          <jats:p>\n            <jats:bold>Graphical Abstract [created With Biorender.com]<\/jats:bold>\n          <\/jats:p>","DOI":"10.1007\/s11357-024-01359-x","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T15:02:44Z","timestamp":1727449364000},"page":"457-482","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Monoamine alterations in Alzheimer\u2019s disease and their implications in comorbid neuropsychiatric symptoms"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4058-3760","authenticated-orcid":false,"given":"Shalini","family":"Saggu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ava","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mae","family":"Aida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasibur","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Pless","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Destany","family":"Ware","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferenc","family":"Deak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"key":"1359_CR1","doi-asserted-by":"publisher","unstructured":"2024 Alzheimer's disease facts and figures. Alzheimers Demen. 2024;20(5):3708\u20133821.\u00a0https:\/\/doi.org\/10.1002\/alz.13809","DOI":"10.1002\/alz.13809"},{"key":"1359_CR2","doi-asserted-by":"publisher","unstructured":"Association AS. 2016 Alzheimer\u2019s disease facts and figures. Alzheimers Demen. 2016;12(4):459\u2013509.\u00a0https:\/\/doi.org\/10.1016\/j.jalz.2016.03.001","DOI":"10.1016\/j.jalz.2016.03.001"},{"issue":"1","key":"1359_CR3","first-page":"61","volume":"75","author":"N Graham","year":"2004","unstructured":"Graham N, Emery T, Hodges J. Distinctive cognitive profiles in Alzheimer\u2019s disease and subcortical vascular dementia. J Neurol Neurosurg Psychiatry. 2004;75(1):61\u201371.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1359_CR4","doi-asserted-by":"publisher","unstructured":"Pless A,\u00a0Ware D, Saggu S, Rehman H, Morgan J, Wang Q.\u00a0Understanding neuropsychiatric symptoms in Alzheimer\u2019s disease: challenges and advances in diagnosis and treatment. Front Neurosci. 2023;17:1263771.\u00a0https:\/\/doi.org\/10.3389\/fnins.2023.1263771","DOI":"10.3389\/fnins.2023.1263771"},{"issue":"3","key":"1359_CR5","doi-asserted-by":"publisher","first-page":"219","DOI":"10.5507\/bp.2011.036","volume":"155","author":"M Pohanka","year":"2011","unstructured":"Pohanka M. Cholinesterases, a target of pharmacology and toxicology. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2011;155(3):219\u201329.","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"1359_CR6","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1146\/annurev.med.57.121304.131442","volume":"57","author":"A Lleo","year":"2006","unstructured":"Lleo A, Greenberg S, Growdon J. Current pharmacotherapy for Alzheimer\u2019s disease. Annu Rev Med. 2006;57:513\u201333.","journal-title":"Annu Rev Med"},{"issue":"1","key":"1359_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1517\/14656566.7.1.1","volume":"7","author":"PM Doraiswamy","year":"2006","unstructured":"Doraiswamy PM, Xiong GL. Pharmacological strategies for the prevention of Alzheimer\u2019s disease. Expert Opin Pharmacother. 2006;7(1):1\u201310.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"1359_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/01.wad.0000201847.29836.a5","volume":"20","author":"R Bullock","year":"2006","unstructured":"Bullock R. Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date. Alzheimer Dis Assoc Disord. 2006;20(1):23\u20139.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"1359_CR9","doi-asserted-by":"publisher","first-page":"877143","DOI":"10.3389\/fneur.2022.877143","volume":"13","author":"B Iravani","year":"2022","unstructured":"Iravani B, Abdollahi E, Eslamdoust-Siahestalkhi F, Soleimani R. Neuropsychiatric Symptoms of Alzheimer\u2019s Disease and Caregiver Burden. Front Neurol. 2022;13:877143.","journal-title":"Front Neurol"},{"issue":"1","key":"1359_CR10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12877-022-02762-9","volume":"22","author":"V Garc\u00eda-Mart\u00edn","year":"2022","unstructured":"Garc\u00eda-Mart\u00edn V, et al. Neuropsychiatric symptoms and subsyndromes in patients with different stages of dementia in primary care follow-up (NeDEM project): a cross-sectional study. BMC Geriatr. 2022;22(1):71.","journal-title":"BMC Geriatr"},{"issue":"5","key":"1359_CR11","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1176\/appi.ajp.2014.14040480","volume":"172","author":"ME Peters","year":"2015","unstructured":"Peters ME, et al. Neuropsychiatric symptoms as predictors of progression to severe Alzheimer\u2019s dementia and death: the Cache County Dementia Progression Study. Am J Psychiatry. 2015;172(5):460\u20135.","journal-title":"Am J Psychiatry"},{"issue":"10","key":"1359_CR12","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.2174\/1567205013666160502123607","volume":"13","author":"D Van Dam","year":"2016","unstructured":"Van Dam D, et al. Neuropsychiatric disturbances in Alzheimer\u2019s disease: what have we learned from neuropathological studies? Curr Alzheimer Res. 2016;13(10):1145\u201364.","journal-title":"Curr Alzheimer Res"},{"issue":"8","key":"1359_CR13","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.neubiorev.2013.05.008","volume":"37","author":"L Trillo","year":"2013","unstructured":"Trillo L, et al. Ascending monoaminergic systems alterations in Alzheimer\u2019s disease. Translating basic science into clinical care. Neurosci Biobehav Rev. 2013;37(8):1363\u201379.","journal-title":"Neurosci Biobehav Rev"},{"issue":"2","key":"1359_CR14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1136\/jnnp.45.2.113","volume":"45","author":"D Mann","year":"1982","unstructured":"Mann D, Yates P, Hawkes J. The noradrenergic system in Alzheimer and multi-infarct dementias. J Neurol Neurosurg Psychiatry. 1982;45(2):113.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"1359_CR15","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/j.1365-2990.1984.tb00351.x","volume":"10","author":"D Mann","year":"1984","unstructured":"Mann D, Yates P, Marcyniuk B. Alzheimer\u2019s presenile dementia, senile dementia of Alzheimer type and Down\u2019s syndrome in middle age form an age related continuum of pathological changes. Neuropathol Appl Neurobiol. 1984;10(3):185\u2013207.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"1359_CR16","doi-asserted-by":"publisher","first-page":"927804","DOI":"10.1155\/2014\/927804","volume":"2014","author":"XL Li","year":"2014","unstructured":"Li XL, et al. Behavioral and psychological symptoms in Alzheimer\u2019s disease. Biomed Res Int. 2014;2014:927804.","journal-title":"Biomed Res Int"},{"issue":"6","key":"1359_CR17","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/jnnp.71.6.777","volume":"71","author":"C Holmes","year":"2001","unstructured":"Holmes C, et al. Psychosis and aggression in Alzheimer\u2019s disease: the effect of dopamine receptor gene variation. J Neurol Neurosurg Psychiatry. 2001;71(6):777\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2\u20133","key":"1359_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.neulet.2004.08.006","volume":"370","author":"B Borroni","year":"2004","unstructured":"Borroni B, et al. Catechol-O-methyltransferase gene polymorphism is associated with risk of psychosis in Alzheimer Disease. Neurosci Lett. 2004;370(2\u20133):127\u20139.","journal-title":"Neurosci Lett"},{"key":"1359_CR19","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.dadm.2017.11.001","volume":"10","author":"AD Dekker","year":"2018","unstructured":"Dekker AD, et al. Monoaminergic impairment in Down syndrome with Alzheimer\u2019s disease compared to early-onset Alzheimer\u2019s disease. Alzheimers Dement (Amst). 2018;10:99\u2013111.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"1","key":"1359_CR20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/BF00313207","volume":"224","author":"V Argentiero","year":"1980","unstructured":"Argentiero V, Tavolato B. Dopamine (DA) and serotonin metabolic levels in the cerebrospinal fluid (CSF) in Alzheimer\u2019s presenile dementia under basic conditions and after stimulation with cerebral cortex phospholipids (BC-PL). J Neurol. 1980;224(1):53\u20138.","journal-title":"J Neurol"},{"issue":"5","key":"1359_CR21","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1136\/jnnp.47.5.481","volume":"47","author":"AM Palmer","year":"1984","unstructured":"Palmer AM, et al. Monoamine metabolite concentrations in lumbar cerebrospinal fluid of patients with histologically verified Alzheimer\u2019s dementia. J Neurol Neurosurg Psychiatry. 1984;47(5):481\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"1359_CR22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1001\/archneur.1985.04060020037011","volume":"42","author":"L Volicer","year":"1985","unstructured":"Volicer L, et al. Serotonin and 5-hydroxyindoleacetic acid in CSF. Difference in Parkinson\u2019s disease and dementia of the Alzheimer\u2019s type. Arch Neurol. 1985;42(2):127\u20139.","journal-title":"Arch Neurol"},{"issue":"4","key":"1359_CR23","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1001\/jamapsychiatry.2021.4363","volume":"79","author":"DP Devanand","year":"2022","unstructured":"Devanand DP, Lee S, Huey ED, Goldberg TE. Associations between neuropsychiatric symptoms and neuropathological diagnoses of Alzheimer disease and related dementias. JAMA Psychiat. 2022;79(4):359\u201367.","journal-title":"JAMA Psychiat"},{"key":"1359_CR24","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.phrs.2018.01.016","volume":"130","author":"M D\u2019Amelio","year":"2018","unstructured":"D\u2019Amelio M, Puglisi-Allegra S, Mercuri N. The role of dopaminergic midbrain in Alzheimer\u2019s disease: translating basic science into clinical practice. Pharmacol Res. 2018;130:414\u20139.","journal-title":"Pharmacol Res"},{"issue":"1","key":"1359_CR25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3233\/JAD-180688","volume":"66","author":"AJ Ehrenberg","year":"2018","unstructured":"Ehrenberg AJ, et al. Neuropathologic correlates of psychiatric symptoms in Alzheimer\u2019s disease. J Alzheimers Dis. 2018;66(1):115\u201326.","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"1359_CR26","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0022-3999(02)00304-5","volume":"53","author":"P Cassano","year":"2002","unstructured":"Cassano P, Fava M. Depression and public health: an overview. J Psychosom Res. 2002;53(4):849\u201357.","journal-title":"J Psychosom Res"},{"issue":"8","key":"1359_CR27","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.neurobiolaging.2005.06.003","volume":"27","author":"M Garcia-Alloza","year":"2006","unstructured":"Garcia-Alloza M, et al. Involvement of the GABAergic system in depressive symptoms of Alzheimer\u2019s disease. Neurobiol Aging. 2006;27(8):1110\u20137.","journal-title":"Neurobiol Aging"},{"issue":"11","key":"1359_CR28","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.jagp.2013.01.043","volume":"21","author":"LB Zahodne","year":"2013","unstructured":"Zahodne LB, et al. Are apathy and depression independently associated with longitudinal trajectories of cortical atrophy in mild cognitive impairment? Am J Geriatr Psychiatry. 2013;21(11):1098\u2013106.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"1","key":"1359_CR29","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13195-015-0096-3","volume":"7","author":"MA Nowrangi","year":"2015","unstructured":"Nowrangi MA, Lyketsos CG, Rosenberg PB. Principles and management of neuropsychiatric symptoms in Alzheimer\u2019s dementia. Alzheimer\u2019s Res Ther. 2015;7(1):12.","journal-title":"Alzheimer's Res Ther"},{"issue":"2","key":"1359_CR30","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.archger.2008.09.002","volume":"49","author":"P Tagariello","year":"2009","unstructured":"Tagariello P, Girardi P, Amore M. Depression and apathy in dementia: same syndrome or different constructs? A critical review. Arch Gerontol Geriatr. 2009;49(2):246\u20139.","journal-title":"Arch Gerontol Geriatr"},{"issue":"1","key":"1359_CR31","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13024-021-00456-1","volume":"16","author":"Y Chen","year":"2021","unstructured":"Chen Y, Dang M, Zhang Z. Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer\u2019s disease: a systematic review of symptom-general and\u2013specific lesion patterns. Mol Neurodegener. 2021;16(1):38.","journal-title":"Mol Neurodegener"},{"issue":"1","key":"1359_CR32","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.pscychresns.2013.11.002","volume":"221","author":"S Terada","year":"2014","unstructured":"Terada S, et al. Depressive symptoms and regional cerebral blood flow in Alzheimer\u2019s disease. Psychiatry Res Neuroimaging. 2014;221(1):86\u201391.","journal-title":"Psychiatry Res Neuroimaging"},{"issue":"6","key":"1359_CR33","first-page":"417","volume":"29","author":"S Campbell","year":"2004","unstructured":"Campbell S, Macqueen G. The role of the hippocampus in the pathophysiology of major depression. J Psychiatry Neurosci. 2004;29(6):417\u201326.","journal-title":"J Psychiatry Neurosci"},{"issue":"5","key":"1359_CR34","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1503\/jpn.100002","volume":"35","author":"NV Malykhin","year":"2010","unstructured":"Malykhin NV, Carter R, Seres P, Coupland NJ. Structural changes in the hippocampus in major depressive disorder: contributions of disease and treatment. J Psychiatry Neurosci. 2010;35(5):337\u201343.","journal-title":"J Psychiatry Neurosci"},{"key":"1359_CR35","doi-asserted-by":"publisher","first-page":"644317","DOI":"10.3389\/fneur.2021.644317","volume":"12","author":"C Carrarini","year":"2021","unstructured":"Carrarini C, et al. Agitation and dementia: prevention and treatment strategies in acute and chronic conditions. Front Neurol. 2021;12:644317.","journal-title":"Front Neurol"},{"key":"1359_CR36","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.mam.2015.05.005","volume":"43","author":"PB Rosenberg","year":"2015","unstructured":"Rosenberg PB, Nowrangi MA, Lyketsos CG. Neuropsychiatric symptoms in Alzheimer\u2019s disease: what might be associated brain circuits? Mol Aspects Med. 2015;43:25\u201337.","journal-title":"Mol Aspects Med"},{"issue":"8","key":"1359_CR37","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1001\/archneur.61.8.1249","volume":"61","author":"F Assal","year":"2004","unstructured":"Assal F, et al. Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease. Arch Neurol. 2004;61(8):1249\u201353.","journal-title":"Arch Neurol"},{"issue":"1","key":"1359_CR38","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3233\/JAD-2010-1223","volume":"19","author":"L Serra","year":"2010","unstructured":"Serra L, et al. Grey and white matter changes at different stages of Alzheimer\u2019s disease. J Alzheimers Dis. 2010;19(1):147\u201359.","journal-title":"J Alzheimers Dis"},{"issue":"Pt 9","key":"1359_CR39","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1093\/brain\/awn151","volume":"131","author":"PD Bruen","year":"2008","unstructured":"Bruen PD, McGeown WJ, Shanks MF, Venneri A. Neuroanatomical correlates of neuropsychiatric symptoms in Alzheimer\u2019s disease. Brain. 2008;131(Pt 9):2455\u201363.","journal-title":"Brain"},{"key":"1359_CR40","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s00429-010-0262-0","volume":"214","author":"V Menon","year":"2010","unstructured":"Menon V, Uddin LQ. Saliency, switching, attention and control: a network model of insula function. Brain Struct Funct. 2010;214:655\u201367.","journal-title":"Brain Struct Funct"},{"issue":"6","key":"1359_CR41","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1212\/WNL.0000000000001238","volume":"84","author":"MC Masters","year":"2015","unstructured":"Masters MC, Morris JC, Roe CM. \u201cNoncognitive\u201d symptoms of early Alzheimer disease: a longitudinal analysis. Neurology. 2015;84(6):617\u201322.","journal-title":"Neurology"},{"issue":"1","key":"1359_CR42","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3233\/JAD-131289","volume":"39","author":"J Horvath","year":"2014","unstructured":"Horvath J, et al. Neuropathology of parkinsonism in patients with pure Alzheimer\u2019s disease. J Alzheimers Dis. 2014;39(1):115\u201320.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"1359_CR43","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3233\/JAD-130899","volume":"37","author":"K Iqbal","year":"2013","unstructured":"Iqbal K, Flory M, Soininen H. Clinical symptoms and symptom signatures of Alzheimer\u2019s disease subgroups. J Alzheimers Dis. 2013;37(3):475\u201381.","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"1359_CR44","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2174\/1871527311312040010","volume":"12","author":"G Koch","year":"2013","unstructured":"Koch G, et al. Frailty among Alzheimer\u2019s disease patients. CNS Neurol Disord Drug Targets. 2013;12(4):507\u201311.","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"9","key":"1359_CR45","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/archneurol.2011.189","volume":"68","author":"C Schmidt","year":"2011","unstructured":"Schmidt C, et al. Rapidly progressive Alzheimer disease. Arch Neurol. 2011;68(9):1124\u201330.","journal-title":"Arch Neurol"},{"issue":"2","key":"1359_CR46","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1159\/000103914","volume":"24","author":"LG Apostolova","year":"2007","unstructured":"Apostolova LG, et al. Structural correlates of apathy in Alzheimer\u2019s disease. Dement Geriatr Cogn Disord. 2007;24(2):91\u20137.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"4","key":"1359_CR47","first-page":"646","volume":"27","author":"KL Lanct\u00f4t","year":"2002","unstructured":"Lanct\u00f4t KL, et al. Central serotonergic activity is related to the aggressive behaviors of Alzheimer\u2019s disease. Neuropsychopharmacology. 2002;27(4):646\u201354.","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"1359_CR48","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.neurobiolaging.2006.10.011","volume":"29","author":"AL Pritchard","year":"2008","unstructured":"Pritchard AL, et al. Role of 5HT2A and 5HT2C polymorphisms in behavioural and psychological symptoms of Alzheimer\u2019s disease. Neurobiol Aging. 2008;29(3):341\u20137.","journal-title":"Neurobiol Aging"},{"key":"1359_CR49","first-page":"339","volume":"10","author":"K Banno","year":"2014","unstructured":"Banno K, et al. Neural basis of three dimensions of agitated behaviors in patients with Alzheimer disease. Neuropsychiatr Dis Treat. 2014;10:339\u201348.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"2","key":"1359_CR50","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1177\/1533317513507373","volume":"29","author":"MS Rafii","year":"2014","unstructured":"Rafii MS, et al. Neuropsychiatric symptoms and regional neocortical atrophy in mild cognitive impairment and Alzheimer\u2019s disease. Am J Alzheimers Dis Other Demen. 2014;29(2):159\u201365.","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"1359_CR51","doi-asserted-by":"publisher","unstructured":"Mah L, Binns MA, Steffens DC. Alzheimer\u2019s Disease Neuroimaging Initiative. Anxiety symptoms in amnestic mild cognitive impairment are associated with medial temporal atrophy and predict conversion to Alzheimer disease. Am J Geriatr Psychiatry. 2015;23(5):466\u201376.\u00a0https:\/\/doi.org\/10.1016\/j.jagp.2014.10.005","DOI":"10.1016\/j.jagp.2014.10.005"},{"issue":"2","key":"1359_CR52","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3233\/JAD-2010-100048","volume":"21","author":"L Serra","year":"2010","unstructured":"Serra L, et al. Are the behavioral symptoms of Alzheimer\u2019s disease directly associated with neurodegeneration? J Alzheimers Dis. 2010;21(2):627\u201339.","journal-title":"J Alzheimers Dis"},{"issue":"8","key":"1359_CR53","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/gps.2418","volume":"25","author":"YA Berlow","year":"2010","unstructured":"Berlow YA, et al. Neuropsychiatric correlates of white matter hyperintensities in Alzheimer\u2019s disease. Int J Geriatr Psychiatry. 2010;25(8):780\u20138.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"1","key":"1359_CR54","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3233\/ADR-210294","volume":"5","author":"MF Mendez","year":"2021","unstructured":"Mendez MF. The relationship between anxiety and Alzheimer\u2019s disease. J Alzheimers Dis Rep. 2021;5(1):171\u20137.","journal-title":"J Alzheimers Dis Rep"},{"issue":"8","key":"1359_CR55","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.neubiorev.2013.05.008","volume":"37","author":"L Trillo","year":"2013","unstructured":"Trillo L, et al. Ascending monoaminergic systems alterations in Alzheimer\u2019s disease. Translating basic science into clinical care. Neurosci Biobehav Rev. 2013;37(8):1363\u201379.","journal-title":"Neurosci Biobehav Rev"},{"issue":"4","key":"1359_CR56","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.3390\/ijms24043841","volume":"24","author":"Z Yang","year":"2023","unstructured":"Yang Z, Zou Y, Wang L. Neurotransmitters in prevention and treatment of Alzheimer\u2019s disease. Int J Mol Sci. 2023;24(4):3841.","journal-title":"Int J Mol Sci"},{"key":"1359_CR57","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.pneurobio.2016.04.001","volume":"151","author":"G \u0160imi\u0107","year":"2017","unstructured":"\u0160imi\u0107 G, et al. Monoaminergic neuropathology in Alzheimer\u2019s disease. Prog Neurobiol. 2017;151:101\u201338.","journal-title":"Prog Neurobiol"},{"issue":"Suppl 1","key":"1359_CR58","first-page":"9","volume":"7","author":"C Moret","year":"2011","unstructured":"Moret C, Briley M. The importance of norepinephrine in depression. Neuropsychiatr Dis Treat. 2011;7(Suppl 1):9\u201313.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"1359_CR59","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.mehy.2013.11.016","volume":"82","author":"R Pamphlett","year":"2014","unstructured":"Pamphlett R. Uptake of environmental toxicants by the locus ceruleus: a potential trigger for neurodegenerative, demyelinating and psychiatric disorders. Med Hypotheses. 2014;82(1):97\u2013104.","journal-title":"Med Hypotheses"},{"key":"1359_CR60","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00401-005-0004-1","volume":"111","author":"H Fujishiro","year":"2006","unstructured":"Fujishiro H, et al. Depletion of cholinergic neurons in the nucleus of the medial septum and the vertical limb of the diagonal band in dementia with Lewy bodies. Acta Neuropathol. 2006;111:109\u201314.","journal-title":"Acta Neuropathol"},{"issue":"1\u20136","key":"1359_CR61","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/0361-9230(82)90142-3","volume":"9","author":"SE Loughlin","year":"1982","unstructured":"Loughlin SE, Foote SL, Fallon JH. Locus coeruleus projections to cortex: topography, morphology and collateralization. Brain Res Bull. 1982;9(1\u20136):287\u201394.","journal-title":"Brain Res Bull"},{"issue":"11","key":"1359_CR62","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1523\/JNEUROSCI.09-11-03803.1989","volume":"9","author":"S Oleskevich","year":"1989","unstructured":"Oleskevich S, Descarries L, Lacaille J-C. Quantified distribution of the noradrenaline innervation in the hippocampus of adult rat. J Neurosci. 1989;9(11):3803\u201315.","journal-title":"J Neurosci"},{"issue":"4","key":"1359_CR63","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.3233\/JAD-200187","volume":"77","author":"S Dutt","year":"2020","unstructured":"Dutt S, et al. Brainstem volumetric integrity in preclinical and prodromal Alzheimer\u2019s disease. J Alzheimers Dis. 2020;77(4):1579\u201394.","journal-title":"J Alzheimers Dis"},{"key":"1359_CR64","doi-asserted-by":"publisher","first-page":"105167","DOI":"10.1016\/j.neubiorev.2023.105167","volume":"149","author":"IF Orlando","year":"2023","unstructured":"Orlando IF, et al. Noradrenergic and cholinergic systems take centre stage in neuropsychiatric diseases of ageing. Neurosci Biobehav Rev. 2023;149:105167.","journal-title":"Neurosci Biobehav Rev"},{"issue":"5","key":"1359_CR65","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/ana.410320510","volume":"32","author":"DC German","year":"1992","unstructured":"German DC, et al. Disease-specific patterns of locus coeruleus cell loss. Ann Neurol. 1992;32(5):667\u201376.","journal-title":"Ann Neurol"},{"key":"1359_CR66","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.dadm.2019.02.001","volume":"11","author":"MJ Betts","year":"2019","unstructured":"Betts MJ, et al. Locus coeruleus MRI contrast is reduced in Alzheimer\u2019s disease dementia and correlates with CSF A\u03b2 levels. Alzheimers Dement (Amst). 2019;11:281\u20135.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"5","key":"1359_CR67","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/s41386-022-01293-6","volume":"47","author":"CM Cassidy","year":"2022","unstructured":"Cassidy CM, et al. Association of locus coeruleus integrity with Braak stage and neuropsychiatric symptom severity in Alzheimer\u2019s disease. Neuropsychopharmacology. 2022;47(5):1128\u201336.","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"1359_CR68","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/s41380-019-0437-x","volume":"26","author":"HI Jacobs","year":"2021","unstructured":"Jacobs HI, Riphagen JM, Ramakers IH, Verhey FR. Alzheimer\u2019s disease pathology: pathways between central norepinephrine activity, memory, and neuropsychiatric symptoms. Mol Psychiatry. 2021;26(3):897\u2013906.","journal-title":"Mol Psychiatry"},{"issue":"1","key":"1359_CR69","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41398-020-0808-8","volume":"10","author":"X Du","year":"2020","unstructured":"Du X, et al. Reduction of depression-like behavior in rat model induced by ShRNA targeting norepinephrine transporter in locus coeruleus. Transl Psychiatry. 2020;10(1):130.","journal-title":"Transl Psychiatry"},{"issue":"4","key":"1359_CR70","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.arcmed.2018.08.010","volume":"49","author":"H Rui","year":"2018","unstructured":"Rui H, et al. Meta-analysis on the association between norepinephrine transporter gene rs2242446, rs5569 polymorphisms and risk of major depressive disorder. Arch Med Res. 2018;49(4):261\u20139.","journal-title":"Arch Med Res"},{"key":"1359_CR71","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.brainres.2014.10.055","volume":"1594","author":"J Solich","year":"2015","unstructured":"Solich J, et al. Norepinephrine transporter knock-out alters expression of the genes connected with antidepressant drugs action. Brain Res. 2015;1594:284\u201392.","journal-title":"Brain Res"},{"issue":"4","key":"1359_CR72","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1111\/j.1471-4159.2005.03598.x","volume":"96","author":"R Gilsbach","year":"2006","unstructured":"Gilsbach R, et al. Norepinephrine transporter knockout-induced up-regulation of brain alpha2A\/C-adrenergic receptors. J Neurochem. 2006;96(4):1111\u201320.","journal-title":"J Neurochem"},{"key":"1359_CR73","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.cobeha.2017.12.015","volume":"22","author":"L Passamonti","year":"2018","unstructured":"Passamonti L, Lansdall CJ, Rowe JB. The neuroanatomical and neurochemical basis of apathy and impulsivity in frontotemporal lobar degeneration. Curr Opin Behav Sci. 2018;22:14\u201320.","journal-title":"Curr Opin Behav Sci"},{"issue":"6","key":"1359_CR74","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1002\/alz.12252","volume":"17","author":"M Malpetti","year":"2021","unstructured":"Malpetti M, et al. Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes. Alzheimers Dement. 2021;17(6):969\u201383.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"1359_CR75","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.neuron.2015.07.002","volume":"87","author":"JG McCall","year":"2015","unstructured":"McCall JG, et al. CRH engagement of the locus coeruleus noradrenergic system mediates stress-induced anxiety. Neuron. 2015;87(3):605\u201320.","journal-title":"Neuron"},{"issue":"3","key":"1359_CR76","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/nrn.2017.8","volume":"18","author":"JW Dalley","year":"2017","unstructured":"Dalley JW, Robbins TW. Fractionating impulsivity: neuropsychiatric implications. Nat Rev Neurosci. 2017;18(3):158\u201371.","journal-title":"Nat Rev Neurosci"},{"issue":"2","key":"1359_CR77","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.expneurol.2012.05.008","volume":"236","author":"JH Yang","year":"2012","unstructured":"Yang JH, et al. Norepinephrine differentially modulates the innate inflammatory response provoked by amyloid-\u03b2 peptide via action at \u03b2-adrenoceptors and activation of cAMP\/PKA pathway in human THP-1 macrophages. Exp Neurol. 2012;236(2):199\u2013206.","journal-title":"Exp Neurol"},{"issue":"1\u20132","key":"1359_CR78","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0169-328X(00)00168-6","volume":"84","author":"P Szot","year":"2000","unstructured":"Szot P, et al. Tyrosine hydroxylase and norepinephrine transporter mRNA expression in the locus coeruleus in Alzheimer\u2019s disease. Mol Brain Res. 2000;84(1\u20132):135\u201340.","journal-title":"Mol Brain Res"},{"issue":"3","key":"1359_CR79","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/cne.902870308","volume":"287","author":"V Chan-Palay","year":"1989","unstructured":"Chan-Palay V, Asan E. Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson\u2019s disease with and without dementia and depression. Journal of Comparative Neurology. 1989;287(3):373\u201392.","journal-title":"Journal of Comparative Neurology"},{"issue":"3","key":"1359_CR80","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/0304-3940(86)90336-8","volume":"64","author":"B Marcyniuk","year":"1986","unstructured":"Marcyniuk B, Mann D, Yates P. Loss of nerve cells from locus coeruleus in Alzheimer\u2019s disease is topographically arranged. Neurosci Lett. 1986;64(3):247\u201352.","journal-title":"Neurosci Lett"},{"issue":"5","key":"1359_CR81","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0301-0082(02)00023-0","volume":"67","author":"ME Gibbs","year":"2002","unstructured":"Gibbs ME, Summers RJ. Role of adrenoceptor subtypes in memory consolidation. Prog Neurobiol. 2002;67(5):345\u201391.","journal-title":"Prog Neurobiol"},{"issue":"1","key":"1359_CR82","doi-asserted-by":"publisher","first-page":"e12257","DOI":"10.1002\/trc2.12257","volume":"8","author":"Y Chen","year":"2022","unstructured":"Chen Y, Chen T, Hou R. Locus coeruleus in the pathogenesis of Alzheimer\u2019s disease: a systematic review. Alzheimers Dement (N Y). 2022;8(1):e12257.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"3","key":"1359_CR83","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/ggi.12280","volume":"15","author":"J Takahashi","year":"2015","unstructured":"Takahashi J, et al. Detection of changes in the locus coeruleus in patients with mild cognitive impairment and Alzheimer\u2019s disease: high-resolution fast spin-echo T 1-weighted imaging. Geriatr Gerontol Int. 2015;15(3):334\u201340.","journal-title":"Geriatr Gerontol Int"},{"issue":"11","key":"1359_CR84","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1097\/01.wnr.0000227984.84927.a7","volume":"17","author":"M Sasaki","year":"2006","unstructured":"Sasaki M, et al. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson\u2019s disease. NeuroReport. 2006;17(11):1215\u20138.","journal-title":"NeuroReport"},{"issue":"2","key":"1359_CR85","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/j.1471-4159.2006.03717.x","volume":"97","author":"P Mandela","year":"2006","unstructured":"Mandela P, Ordway GA. The norepinephrine transporter and its regulation. J Neurochem. 2006;97(2):310\u201333.","journal-title":"J Neurochem"},{"issue":"12","key":"1359_CR86","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1358\/dof.2004.029.12.855246","volume":"29","author":"J Zhou","year":"2004","unstructured":"Zhou J. Norepinephrine transporter inhibitors and their therapeutic potential. Drugs Future. 2004;29(12):1235\u201344.","journal-title":"Drugs Future"},{"key":"1359_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40478-017-0411-2","volume":"5","author":"SC Kelly","year":"2017","unstructured":"Kelly SC, et al. Locus coeruleus cellular and molecular pathology during the progression of Alzheimer\u2019s disease. Acta Neuropathol Commun. 2017;5:1\u201314.","journal-title":"Acta Neuropathol Commun"},{"issue":"21","key":"1359_CR88","doi-asserted-by":"publisher","first-page":"15291","DOI":"10.1074\/jbc.M113.458901","volume":"288","author":"S Gyoneva","year":"2013","unstructured":"Gyoneva S, Traynelis SF. Norepinephrine modulates the motility of resting and activated microglia via different adrenergic receptors. J Biol Chem. 2013;288(21):15291\u2013302.","journal-title":"J Biol Chem"},{"issue":"11","key":"1359_CR89","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1038\/s41593-019-0511-3","volume":"22","author":"YU Liu","year":"2019","unstructured":"Liu YU, et al. Neuronal network activity controls microglial process surveillance in awake mice via norepinephrine signaling. Nat Neurosci. 2019;22(11):1771\u201381.","journal-title":"Nat Neurosci"},{"issue":"5","key":"1359_CR90","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00401-020-02248-1","volume":"141","author":"BJ Matchett","year":"2021","unstructured":"Matchett BJ, Grinberg LT, Theofilas P, Murray ME. The mechanistic link between selective vulnerability of the locus coeruleus and neurodegeneration in Alzheimer\u2019s disease. Acta Neuropathol. 2021;141(5):631\u201350.","journal-title":"Acta Neuropathol"},{"key":"1359_CR91","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.brainres.2018.01.001","volume":"1702","author":"M Gannon","year":"2019","unstructured":"Gannon M, Wang Q. Complex noradrenergic dysfunction in Alzheimer\u2019s disease: low norepinephrine input is not always to blame. Brain Res. 2019;1702:12\u20136.","journal-title":"Brain Res"},{"issue":"1","key":"1359_CR92","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1176\/ajp.154.1.25","volume":"154","author":"R Elrod","year":"1997","unstructured":"Elrod R, et al. Effects of Alzheimer\u2019s disease severity on cerebrospinal fluid norepinephrine concentration. Am J Psychiatry. 1997;154(1):25\u201330.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"1359_CR93","first-page":"340","volume":"26","author":"M Oishi","year":"1996","unstructured":"Oishi M, et al. Laboratory examinations correlated with severity of dementia. Ann Clin Lab Sci. 1996;26(4):340\u20135.","journal-title":"Ann Clin Lab Sci"},{"issue":"526","key":"1359_CR94","doi-asserted-by":"publisher","first-page":"eaay6931","DOI":"10.1126\/scitranslmed.aay6931","volume":"12","author":"F Zhang","year":"2020","unstructured":"Zhang F, et al. \u03b2-amyloid redirects norepinephrine signaling to activate the pathogenic GSK3\u03b2\/tau cascade. Sci Transl Med. 2020;12(526):eaay6931.","journal-title":"Sci Transl Med"},{"issue":"48","key":"1359_CR95","doi-asserted-by":"publisher","first-page":"17296","DOI":"10.1073\/pnas.1409513111","volume":"111","author":"Y Chen","year":"2014","unstructured":"Chen Y, et al. \u03b12A adrenergic receptor promotes amyloidogenesis through disrupting APP-SorLA interaction. Proc Natl Acad Sci. 2014;111(48):17296\u2013301.","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"1359_CR96","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/sj.npp.1301518","volume":"33","author":"L Kenton","year":"2008","unstructured":"Kenton L, Boon F, Cain DP. Combined but not individual administration of \u03b2-adrenergic and serotonergic antagonists impairs water maze acquisition in the rat. Neuropsychopharmacology. 2008;33(6):1298\u2013311.","journal-title":"Neuropsychopharmacology"},{"issue":"26","key":"1359_CR97","doi-asserted-by":"publisher","first-page":"9347","DOI":"10.1073\/pnas.0502315102","volume":"102","author":"M Ouyang","year":"2005","unstructured":"Ouyang M, Thomas SA. A requirement for memory retrieval during and after long-term extinction learning. Proc Natl Acad Sci. 2005;102(26):9347\u201352.","journal-title":"Proc Natl Acad Sci"},{"key":"1359_CR98","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.pbb.2014.09.013","volume":"127","author":"E Ruetti","year":"2014","unstructured":"Ruetti E, Justel N, Mustaca A, Boccia M. Corticosterone and propranolol\u2019s role on taste recognition memory. Pharmacol Biochem Behav. 2014;127:37\u201341.","journal-title":"Pharmacol Biochem Behav"},{"issue":"7","key":"1359_CR99","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1038\/sj.npp.1300163","volume":"28","author":"AJ Saber","year":"2003","unstructured":"Saber AJ, Cain DP. Combined \u03b2-adrenergic and cholinergic antagonism produces behavioral and cognitive impairments in the water maze: implications for Alzheimer disease and pharmacotherapy with \u03b2-adrenergic antagonists. Neuropsychopharmacology. 2003;28(7):1247\u201356.","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"1359_CR100","first-page":"231","volume":"5","author":"F Taherian","year":"2014","unstructured":"Taherian F, et al. Propranolol\u2013induced impairment of contextual fear memory reconsolidation in rats: a similar effect on weak and strong recent and remote memories. Basic and Clinical Neuroscience. 2014;5(3):231.","journal-title":"Basic and Clinical Neuroscience"},{"issue":"10","key":"1359_CR101","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1017\/S1461145713000631","volume":"16","author":"M Dobarro","year":"2013","unstructured":"Dobarro M, Gerenu G, Ram\u00edrez MJ. Propranolol reduces cognitive deficits, amyloid and tau pathology in Alzheimer\u2019s transgenic mice. Int J Neuropsychopharmacol. 2013;16(10):2245\u201357.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1359_CR102","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.neuropharm.2012.06.047","volume":"64","author":"M Dobarro","year":"2013","unstructured":"Dobarro M, Orejana L, Aguirre N, Ram\u00edrez MJ. Propranolol restores cognitive deficits and improves amyloid and Tau pathologies in a senescence-accelerated mouse model. Neuropharmacology. 2013;64:137\u201344.","journal-title":"Neuropharmacology"},{"issue":"4","key":"1359_CR103","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.neurobiolaging.2012.09.010","volume":"34","author":"L Katsouri","year":"2013","unstructured":"Katsouri L, et al. Prazosin, an \u03b11-adrenoceptor antagonist, prevents memory deterioration in the APP23 transgenic mouse model of Alzheimer\u2019s disease. Neurobiol Aging. 2013;34(4):1105\u201315.","journal-title":"Neurobiol Aging"},{"issue":"9","key":"1359_CR104","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1097\/JGP.0b013e3181ab8c61","volume":"17","author":"LY Wang","year":"2009","unstructured":"Wang LY, et al. Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. Am J Geriatr Psychiatry. 2009;17(9):744\u201351.","journal-title":"Am J Geriatr Psychiatry"},{"key":"1359_CR105","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.neulet.2019.03.050","volume":"704","author":"S Chakraborty","year":"2019","unstructured":"Chakraborty S, et al. Serotonergic system, cognition, and BPSD in Alzheimer\u2019s disease. Neurosci Lett. 2019;704:36\u201344.","journal-title":"Neurosci Lett"},{"issue":"1","key":"1359_CR106","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.pneurobio.2012.06.010","volume":"99","author":"JJ Rodr\u00edguez","year":"2012","unstructured":"Rodr\u00edguez JJ, Noristani HN, Verkhratsky A. The serotonergic system in ageing and Alzheimer\u2019s disease. Prog Neurobiol. 2012;99(1):15\u201341.","journal-title":"Prog Neurobiol"},{"issue":"1","key":"1359_CR107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13041-017-0306-y","volume":"10","author":"CN Yohn","year":"2017","unstructured":"Yohn CN, Gergues MM, Samuels BA. The role of 5-HT receptors in depression. Mol Brain. 2017;10(1):1\u201312.","journal-title":"Mol Brain"},{"issue":"1","key":"1359_CR108","doi-asserted-by":"publisher","first-page":"32564","DOI":"10.1038\/srep32564","volume":"6","author":"HW Kim","year":"2016","unstructured":"Kim HW, et al. Common variants of HTR3 genes are associated with obsessive-compulsive disorder and its phenotypic expression. Sci Rep. 2016;6(1):32564.","journal-title":"Sci Rep"},{"issue":"12","key":"1359_CR109","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.biopsych.2022.10.012","volume":"93","author":"D Erritzoe","year":"2023","unstructured":"Erritzoe D, et al. Brain serotonin release is reduced in patients with depression: a [11C]Cimbi-36 positron emission tomography study with a d-amphetamine challenge. Biol Psychiat. 2023;93(12):1089\u201398.","journal-title":"Biol Psychiat"},{"key":"1359_CR110","doi-asserted-by":"publisher","unstructured":"Zhan Q, Kong F, Shao S, Zhang B, Huang S. Pathogenesis of depression in Alzheimer\u2019s disease. Neurochem Res. 2024;49(3):548\u201356.\u00a0https:\/\/doi.org\/10.1007\/s11064-023-04061-0","DOI":"10.1007\/s11064-023-04061-0"},{"issue":"1","key":"1359_CR111","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4103\/1673-5374.264445","volume":"15","author":"B Mdawar","year":"2020","unstructured":"Mdawar B, Ghossoub E, Khoury R. Selective serotonin reuptake inhibitors and Alzheimer\u2019s disease. Neural Regen Res. 2020;15(1):41\u20136.","journal-title":"Neural Regen Res"},{"issue":"3","key":"1359_CR112","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1176\/appi.ajp.2017.17040404","volume":"175","author":"C Bartels","year":"2018","unstructured":"Bartels C, et al. Impact of SSRI therapy on risk of conversion from mild cognitive impairment to Alzheimer\u2019s dementia in individuals with previous depression. Am J Psychiatry. 2018;175(3):232\u201341.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"1359_CR113","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/gps.4709","volume":"33","author":"SL Burke","year":"2018","unstructured":"Burke SL, Maramaldi P, Cadet T, Kukull W. Decreasing hazards of Alzheimer\u2019s disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry. 2018;33(1):200\u201311.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"10","key":"1359_CR114","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1001\/archneur.62.10.1601","volume":"62","author":"N Scarmeas","year":"2005","unstructured":"Scarmeas N, et al. Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch Neurol. 2005;62(10):1601\u20138.","journal-title":"Arch Neurol"},{"issue":"4","key":"1359_CR115","doi-asserted-by":"publisher","first-page":"433","DOI":"10.2217\/fnl.13.19","volume":"8","author":"D Collerton","year":"2013","unstructured":"Collerton D, Taylor J-P. Advances in the treatment of visual hallucinations in neurodegenerative diseases. Future Neurol. 2013;8(4):433\u201344.","journal-title":"Future Neurol"},{"issue":"1","key":"1359_CR116","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1515\/tnsci-2016-0007","volume":"7","author":"D \u0160vob\u0160trac","year":"2016","unstructured":"\u0160vob\u0160trac D, Pivac N, M\u00fcck-\u0160eler D. The serotonergic system and cognitive function. Transl Neurosci. 2016;7(1):35\u201349.","journal-title":"Transl Neurosci"},{"issue":"8","key":"1359_CR117","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S0028-3908(99)00010-6","volume":"38","author":"NM Barnes","year":"1999","unstructured":"Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 1999;38(8):1083\u2013152.","journal-title":"Neuropharmacology"},{"issue":"1","key":"1359_CR118","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1176\/jnp.13.1.5","volume":"13","author":"KL Lanct\u00f4t","year":"2001","unstructured":"Lanct\u00f4t KL, Herrmann N, Mazzotta P. Role of serotonin in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci. 2001;13(1):5\u201321.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"1","key":"1359_CR119","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.pneurobio.2012.06.010","volume":"99","author":"JJ Rodriguez","year":"2012","unstructured":"Rodriguez JJ, Noristani HN, Verkhratsky A. The serotonergic system in ageing and Alzheimer\u2019s disease. Prog Neurobiol. 2012;99(1):15\u201341.","journal-title":"Prog Neurobiol"},{"issue":"1","key":"1359_CR120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0197-4580(02)00057-X","volume":"24","author":"SA Lyness","year":"2003","unstructured":"Lyness SA, Zarow C, Chui HC. Neuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: a meta-analysis. Neurobiol Aging. 2003;24(1):1\u201323.","journal-title":"Neurobiol Aging"},{"issue":"4","key":"1359_CR121","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/00005072-198407000-00001","volume":"43","author":"CA Curcio","year":"1984","unstructured":"Curcio CA, Kemper T. Nucleus raphe dorsalis in dementia of the Alzheimer type: neurofibrillary changes and neuronal packing density. J Neuropathol Exp Neurol. 1984;43(4):359\u201368.","journal-title":"J Neuropathol Exp Neurol"},{"key":"1359_CR122","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1007\/BF00227741","volume":"84","author":"G Halliday","year":"1992","unstructured":"Halliday G, et al. Brain stem serotonin-synthesizing neurons in Alzheimer\u2019s disease: a clinicopathological correlation. Acta Neuropathol. 1992;84:638\u201350.","journal-title":"Acta Neuropathol"},{"issue":"2\u20133","key":"1359_CR123","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00213-010-1936-2","volume":"213","author":"MK Lai","year":"2011","unstructured":"Lai MK, et al. Differential involvement of hippocampal serotonin 1A receptors and re-uptake sites in non-cognitive behaviors of Alzheimer\u2019s disease. Psychopharmacology. 2011;213(2\u20133):431\u20139.","journal-title":"Psychopharmacology"},{"issue":"3","key":"1359_CR124","doi-asserted-by":"publisher","first-page":"342","DOI":"10.2174\/156720508784533286","volume":"5","author":"D Weinshenker","year":"2008","unstructured":"Weinshenker D. Functional consequences of locus coeruleus degeneration in Alzheimer\u2019s disease. Curr Alzheimer Res. 2008;5(3):342\u20135.","journal-title":"Curr Alzheimer Res"},{"issue":"3","key":"1359_CR125","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.neurobiolaging.2010.03.023","volume":"33","author":"L Marner","year":"2012","unstructured":"Marner L, et al. Loss of serotonin 2A receptors exceeds loss of serotonergic projections in early Alzheimer\u2019s disease: a combined [11C] DASB and [18F] altanserin-PET study. Neurobiol Aging. 2012;33(3):479\u201387.","journal-title":"Neurobiol Aging"},{"key":"1359_CR126","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/7854_2021_267","volume":"56","author":"A Garcia-Romeu","year":"2022","unstructured":"Garcia-Romeu A, et al. Psychedelics as novel therapeutics in Alzheimer\u2019s disease: rationale and potential mechanisms. Curr Top Behav Neurosci. 2022;56:287\u2013317.","journal-title":"Curr Top Behav Neurosci"},{"key":"1359_CR127","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11920-013-0360-9","volume":"15","author":"AC Khandai","year":"2013","unstructured":"Khandai AC, Aizenstein HJ. Recent advances in neuroimaging biomarkers in geriatric psychiatry. Curr Psychiatry Rep. 2013;15:1\u20139.","journal-title":"Curr Psychiatry Rep"},{"issue":"1","key":"1359_CR128","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/0891988713516540","volume":"27","author":"K Hirao","year":"2014","unstructured":"Hirao K, Smith GS. Positron emission tomography molecular imaging in late-life depression. J Geriatr Psychiatry Neurol. 2014;27(1):13\u201323.","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"1","key":"1359_CR129","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1192\/bjp.165.1.53","volume":"165","author":"H F\u00f6rstl","year":"1994","unstructured":"F\u00f6rstl H, Burns A, Levy R, Cairns N. Neuropathological correlates of psychotic phenomena in confirmed Alzheimer\u2019s disease. Br J Psychiatry. 1994;165(1):53\u20139.","journal-title":"Br J Psychiatry"},{"issue":"6","key":"1359_CR130","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1001\/archneur.1991.00530180075020","volume":"48","author":"GS Zubenko","year":"1991","unstructured":"Zubenko GS, et al. Neuropathologic and neurochemical correlates of psychosis in primary dementia. Arch Neurol. 1991;48(6):619\u201324.","journal-title":"Arch Neurol"},{"issue":"1","key":"1359_CR131","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3233\/JAD-2008-14104","volume":"14","author":"B Marcos","year":"2008","unstructured":"Marcos B, et al. Involvement of an altered 5-HT 6 receptor function in behavioral symptoms of Alzheimer\u2019s disease. J Alzheimers Dis. 2008;14(1):43\u201350.","journal-title":"J Alzheimers Dis"},{"key":"1359_CR132","first-page":"38","volume":"56","author":"SL Dubovsky","year":"1995","unstructured":"Dubovsky SL, Thomas M. Serotonergic mechanisms and current and future psychiatric practice. J Clin Psychiatry. 1995;56:38\u201348.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"1359_CR133","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/00001756-199011000-00021","volume":"1","author":"NM Barnes","year":"1990","unstructured":"Barnes NM, et al. Normal densities of 5-HT3 receptor recognition sites in Alzheimer\u2019s disease. NeuroReport. 1990;1(3):253\u20134.","journal-title":"NeuroReport"},{"issue":"1","key":"1359_CR134","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1176\/jnp.13.1.5","volume":"13","author":"KL Lanct\u00f4t","year":"2001","unstructured":"Lanct\u00f4t KL, Herrmann N, Mazzotta P. Role of serotonin in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci. 2001;13(1):5\u201321.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"9","key":"1359_CR135","doi-asserted-by":"publisher","first-page":"765","DOI":"10.2165\/11590190-000000000-00000","volume":"25","author":"WJ Geldenhuys","year":"2011","unstructured":"Geldenhuys WJ, Van der Schyf CJ. Role of serotonin in Alzheimer\u2019s disease. CNS Drugs. 2011;25(9):765\u201381.","journal-title":"CNS Drugs"},{"issue":"3","key":"1359_CR136","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1073\/pnas.0510237103","volume":"103","author":"V Kepe","year":"2006","unstructured":"Kepe V, et al. Serotonin 1A receptors in the living brain of Alzheimer\u2019s disease patients. Proc Natl Acad Sci. 2006;103(3):702\u20137.","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"1359_CR137","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/sj.npp.1300330","volume":"29","author":"M Garcia-Alloza","year":"2004","unstructured":"Garcia-Alloza M, et al. Differential involvement of 5-HT1B\/1D and 5-HT6 receptors in cognitive and non-cognitive symptoms in Alzheimer\u2019s disease. Neuropsychopharmacology. 2004;29(2):410\u20136.","journal-title":"Neuropsychopharmacology"},{"key":"1359_CR138","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2202-7-36","volume":"7","author":"DE Lorke","year":"2006","unstructured":"Lorke DE, Lu G, Cho E, Yew DT. Serotonin 5-HT 2A and 5-HT 6 receptors in the prefrontal cortex of Alzheimer and normal aging patients. BMC Neurosci. 2006;7:1\u20138.","journal-title":"BMC Neurosci"},{"issue":"1\u20132","key":"1359_CR139","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jns.2009.08.066","volume":"288","author":"SW Tsang","year":"2010","unstructured":"Tsang SW, et al. A serotoninergic basis for hyperphagic eating changes in Alzheimer\u2019s disease. J Neurol Sci. 2010;288(1\u20132):151\u20135.","journal-title":"J Neurol Sci"},{"issue":"4","key":"1359_CR140","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S0197-4580(02)00137-9","volume":"24","author":"J Versijpt","year":"2003","unstructured":"Versijpt J, et al. Imaging of the 5-HT2A system: age-, gender-, and Alzheimer\u2019s disease-related findings. Neurobiol Aging. 2003;24(4):553\u201361.","journal-title":"Neurobiol Aging"},{"issue":"4","key":"1359_CR141","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.3233\/JAD-2010-100117","volume":"20","author":"P Holm","year":"2010","unstructured":"Holm P, et al. Plaque deposition dependent decrease in 5-HT 2A serotonin receptor in A\u03b2PPswe\/PS1dE9 amyloid overexpressing mice. J Alzheimers Dis. 2010;20(4):1201\u201313.","journal-title":"J Alzheimers Dis"},{"key":"1359_CR142","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.neuropharm.2014.11.025","volume":"91","author":"L-B Li","year":"2015","unstructured":"Li L-B, et al. Activation of serotonin2A receptors in the medial septum-diagonal band of Broca complex enhanced working memory in the hemiparkinsonian rats. Neuropharmacology. 2015;91:23\u201333.","journal-title":"Neuropharmacology"},{"issue":"2","key":"1359_CR143","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.bbr.2004.06.024","volume":"157","author":"N Naghdi","year":"2005","unstructured":"Naghdi N, Harooni HE. The effect of intrahippocampal injections of ritanserin (5HT2A\/2C antagonist) and granisetron (5HT3 antagonist) on learning as assessed in the spatial version of the water maze. Behav Brain Res. 2005;157(2):205\u201310.","journal-title":"Behav Brain Res"},{"key":"1359_CR144","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s00213-004-2114-1","volume":"179","author":"AV Terry","year":"2005","unstructured":"Terry AV, Buccafusco JJ, Bartoszyk GD. Selective serotonin 5-HT 2A receptor antagonist EMD 281014 improves delayed matching performance in young and aged rhesus monkeys. Psychopharmacology. 2005;179:725\u201332.","journal-title":"Psychopharmacology"},{"issue":"5","key":"1359_CR145","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.neuron.2011.03.025","volume":"70","author":"S Lammel","year":"2011","unstructured":"Lammel S, Ion DI, Roeper J, Malenka RC. Projection-specific modulation of dopamine neuron synapses by aversive and rewarding stimuli. Neuron. 2011;70(5):855\u201362.","journal-title":"Neuron"},{"issue":"12","key":"1359_CR146","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1002\/mds.25135","volume":"27","author":"JP Bolam","year":"2012","unstructured":"Bolam JP, Pissadaki EK. Living on the edge with too many mouths to feed: why dopamine neurons die. Mov Disord. 2012;27(12):1478\u201383.","journal-title":"Mov Disord"},{"key":"1359_CR147","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3389\/fnagi.2014.00252","volume":"6","author":"A Martorana","year":"2014","unstructured":"Martorana A, Koch G. Is dopamine involved in Alzheimer\u2019s disease? Front Aging Neurosci. 2014;6:252.","journal-title":"Front Aging Neurosci"},{"key":"1359_CR148","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1146\/annurev.neuro.30.051606.094341","volume":"30","author":"HL Fields","year":"2007","unstructured":"Fields HL, Hjelmstad GO, Margolis EB, Nicola SM. Ventral tegmental area neurons in learned appetitive behavior and positive reinforcement. Annu Rev Neurosci. 2007;30:289\u2013316.","journal-title":"Annu Rev Neurosci"},{"issue":"4","key":"1359_CR149","first-page":"554","volume":"37","author":"ND Volkow","year":"1996","unstructured":"Volkow ND, et al. Dopamine transporters decrease with age. J Nucl Med. 1996;37(4):554\u20139.","journal-title":"J Nucl Med"},{"key":"1359_CR150","doi-asserted-by":"publisher","first-page":"1039725","DOI":"10.3389\/fpsyt.2022.1039725","volume":"13","author":"P Krashia","year":"2022","unstructured":"Krashia P, Spoleti E, D\u2019Amelio M. The VTA dopaminergic system as diagnostic and therapeutical target for Alzheimer\u2019s disease. Front Psychiatry. 2022;13:1039725.","journal-title":"Front Psychiatry"},{"key":"1359_CR151","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.neuropsychologia.2017.07.003","volume":"118","author":"C Le Heron","year":"2018","unstructured":"Le Heron C, Apps M, Husain M. The anatomy of apathy: a neurocognitive framework for a motivated behaviour. Neuropsychologia. 2018;118:54\u201367.","journal-title":"Neuropsychologia"},{"issue":"2","key":"1359_CR152","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1159\/000509278","volume":"10","author":"N Udo","year":"2020","unstructured":"Udo N, et al. Apathy in Alzheimer\u2019s disease correlates with the dopamine transporter level in the caudate nuclei. Dement Geriatr Cogn Dis Extra. 2020;10(2):86\u201393.","journal-title":"Dement Geriatr Cogn Dis Extra"},{"issue":"5","key":"1359_CR153","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/j.1755-5949.2010.00161.x","volume":"17","author":"RA Mitchell","year":"2011","unstructured":"Mitchell RA, Herrmann N, Lanct\u00f4t KL. The role of dopamine in symptoms and treatment of apathy in Alzheimer\u2019s disease. CNS Neurosci Ther. 2011;17(5):411\u201327.","journal-title":"CNS Neurosci Ther"},{"key":"1359_CR154","doi-asserted-by":"publisher","unstructured":"Iqbal K, Alonso AD, Gondal JA, Gong CX, Haque N, Khatoon S, et al. Mechanism of neurofibrillary degeneration and pharmacologic therapeutic approach. J Neural Transm Suppl. 2000;59:213\u201322.\u00a0https:\/\/doi.org\/10.1007\/978-3-7091-6781-6_22","DOI":"10.1007\/978-3-7091-6781-6_22"},{"issue":"1","key":"1359_CR155","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00406-022-01417-5","volume":"273","author":"R Manca","year":"2023","unstructured":"Manca R, Valera-Bermejo JM, Venneri A. Accelerated atrophy in dopaminergic targets and medial temporo-parietal regions precedes the onset of delusions in patients with Alzheimer\u2019s disease. Eur Arch Psychiatry Clin Neurosci. 2023;273(1):229\u201341.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"3","key":"1359_CR156","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.3233\/JAD-190954","volume":"75","author":"L Iaccarino","year":"2020","unstructured":"Iaccarino L, et al. In vivo MRI structural and PET metabolic connectivity study of dopamine pathways in Alzheimer\u2019s disease. J Alzheimers Dis. 2020;75(3):1003\u201316.","journal-title":"J Alzheimers Dis"},{"issue":"120","key":"1359_CR157","first-page":"2","volume":"2","author":"G Ayano","year":"2016","unstructured":"Ayano G. Dopamine: receptors, functions, synthesis, pathways, locations and mental disorders: review of literatures. J Ment Disord Treat. 2016;2(120):2.","journal-title":"J Ment Disord Treat"},{"key":"1359_CR158","doi-asserted-by":"publisher","first-page":"107140","DOI":"10.1016\/j.compbiolchem.2019.107140","volume":"83","author":"J Xin","year":"2019","unstructured":"Xin J, Fan T, Guo P, Wang J. Identification of functional divergence sites in dopamine receptors of vertebrates. Comput Biol Chem. 2019;83:107140.","journal-title":"Comput Biol Chem"},{"issue":"1","key":"1359_CR159","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1046\/j.1460-9568.2003.02716.x","volume":"18","author":"N Kemppainen","year":"2003","unstructured":"Kemppainen N, et al. Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer\u2019s disease. Eur J Neurosci. 2003;18(1):149\u201354.","journal-title":"Eur J Neurosci"},{"key":"1359_CR160","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.neuroscience.2014.01.025","volume":"282","author":"CP Ford","year":"2014","unstructured":"Ford CP. The role of D2-autoreceptors in regulating dopamine neuron activity and transmission. Neuroscience. 2014;282:13\u201322.","journal-title":"Neuroscience"},{"issue":"9","key":"1359_CR161","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1038\/s41380-018-0212-4","volume":"25","author":"P Donthamsetti","year":"2020","unstructured":"Donthamsetti P, et al. Arrestin recruitment to dopamine D2 receptor mediates locomotion but not incentive motivation. Mol Psychiatry. 2020;25(9):2086\u2013100.","journal-title":"Mol Psychiatry"},{"key":"1359_CR162","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.brainres.2006.10.049","volume":"1131","author":"U Kumar","year":"2007","unstructured":"Kumar U, Patel SC. Immunohistochemical localization of dopamine receptor subtypes (D1R\u2013D5R) in Alzheimer\u2019s disease brain. Brain Res. 2007;1131:187\u201396.","journal-title":"Brain Res"},{"issue":"3","key":"1359_CR163","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1081\/RRS-200029981","volume":"24","author":"KA Neve","year":"2004","unstructured":"Neve KA, Seamans JK, Trantham-Davidson H. Dopamine receptor signaling. J Recept Signal Transduction. 2004;24(3):165\u2013205.","journal-title":"J Recept Signal Transduction"},{"issue":"1","key":"1359_CR164","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/0893-133X(87)90004-2","volume":"1","author":"P Seeman","year":"1987","unstructured":"Seeman P, et al. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer\u2019s, Parkinson\u2019s, and Huntington\u2019s diseases. Neuropsychopharmacology. 1987;1(1):5\u201315.","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"1359_CR165","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1001\/archneur.58.3.466","volume":"58","author":"RA Sweet","year":"2001","unstructured":"Sweet RA, et al. Alterations of striatal dopamine receptor binding in Alzheimer disease are associated with Lewy body pathology and antemortem psychosis. Arch Neurol. 2001;58(3):466\u201372.","journal-title":"Arch Neurol"},{"issue":"1","key":"1359_CR166","doi-asserted-by":"publisher","first-page":"19412","DOI":"10.1038\/s41598-021-99025-1","volume":"11","author":"Y Gloria","year":"2021","unstructured":"Gloria Y, et al. Dopaminergic dysfunction in the 3xTg-AD mice model of Alzheimer\u2019s disease. Sci Rep. 2021;11(1):19412.","journal-title":"Sci Rep"},{"key":"1359_CR167","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.neurobiolaging.2016.02.021","volume":"41","author":"P Moreno-Castilla","year":"2016","unstructured":"Moreno-Castilla P, et al. Dopaminergic neurotransmission dysfunction induced by amyloid-\u03b2 transforms cortical long-term potentiation into long-term depression and produces memory impairment. Neurobiol Aging. 2016;41:187\u201399.","journal-title":"Neurobiol Aging"},{"issue":"8","key":"1359_CR168","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.neurobiolaging.2007.11.010","volume":"30","author":"O Ambr\u00e9e","year":"2009","unstructured":"Ambr\u00e9e O, et al. Levodopa ameliorates learning and memory deficits in a murine model of Alzheimer\u2019s disease. Neurobiol Aging. 2009;30(8):1192\u2013204.","journal-title":"Neurobiol Aging"},{"issue":"10","key":"1359_CR169","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1101\/lm.026070.112","volume":"19","author":"K Guzm\u00e1n-Ramos","year":"2012","unstructured":"Guzm\u00e1n-Ramos K, et al. Restoration of dopamine release deficits during object recognition memory acquisition attenuates cognitive impairment in a triple transgenic mice model of Alzheimer\u2019s disease. Learn Mem. 2012;19(10):453\u201360.","journal-title":"Learn Mem"},{"issue":"6","key":"1359_CR170","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S0893-133X(98)00044-X","volume":"19","author":"J Joyce","year":"1998","unstructured":"Joyce J, et al. Loss of dopamine D2 receptors in Alzheimer\u2019s disease with parkinsonism but not Parkinson\u2019s or Alzheimer\u2019s disease. Neuropsychopharmacology. 1998;19(6):472\u201380.","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"1359_CR171","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1212\/01.wnl.0000341932.21961.f3","volume":"72","author":"S Reeves","year":"2009","unstructured":"Reeves S, Brown R, Howard R, Grasby P. Increased striatal dopamine (D2\/D3) receptor availability and delusions in Alzheimer disease. Neurology. 2009;72(6):528\u201334.","journal-title":"Neurology"},{"issue":"6","key":"1359_CR172","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/mds.870120609","volume":"12","author":"JN Joyce","year":"1997","unstructured":"Joyce JN, et al. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson\u2019s, Alzheimer\u2019s with parkinsonism, and Alzheimer\u2019s disease. Mov Disord. 1997;12(6):885\u201397.","journal-title":"Mov Disord"},{"key":"1359_CR173","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3389\/fnagi.2014.00252","volume":"6","author":"A Martorana","year":"2014","unstructured":"Martorana A, Koch G. Is dopamine involved in Alzheimer\u2019s disease? Front Aging Neurosci. 2014;6:252.","journal-title":"Front Aging Neurosci"},{"issue":"4","key":"1359_CR174","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.3233\/JAD-181116","volume":"68","author":"O Belbin","year":"2019","unstructured":"Belbin O, et al. The Epistasis Project: A multi-cohort study of the effects of BDNF, DBH, and SORT1 epistasis on Alzheimer\u2019s disease risk. J Alzheimers Dis. 2019;68(4):1535\u201347.","journal-title":"J Alzheimers Dis"},{"key":"1359_CR175","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3389\/fnagi.2019.00175","volume":"11","author":"X Pan","year":"2019","unstructured":"Pan X, et al. Dopamine and dopamine receptors in Alzheimer\u2019s disease: a systematic review and network meta-analysis. Frontiers in Aging Neuroscience. 2019;11:175.","journal-title":"Frontiers in Aging Neuroscience"},{"issue":"4","key":"1359_CR176","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/syn.20603","volume":"63","author":"K Ishibashi","year":"2009","unstructured":"Ishibashi K, et al. Regional analysis of age-related decline in dopamine transporters and dopamine D2-like receptors in human striatum. Synapse. 2009;63(4):282\u201390.","journal-title":"Synapse"},{"issue":"5","key":"1359_CR177","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0197-4580(00)00149-4","volume":"21","author":"V Kaasinen","year":"2000","unstructured":"Kaasinen V, et al. Age-related dopamine D2\/D3 receptor loss in extrastriatal regions of the human brain. Neurobiol Aging. 2000;21(5):683\u20138.","journal-title":"Neurobiol Aging"},{"key":"1359_CR178","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.neurobiolaging.2017.05.006","volume":"57","author":"TM Karrer","year":"2017","unstructured":"Karrer TM, et al. Reduced dopamine receptors and transporters but not synthesis capacity in normal aging adults: a meta-analysis. Neurobiol Aging. 2017;57:36\u201346.","journal-title":"Neurobiol Aging"},{"issue":"52","key":"1359_CR179","doi-asserted-by":"publisher","first-page":"14320","DOI":"10.1523\/JNEUROSCI.3729-08.2008","volume":"28","author":"MN Braskie","year":"2008","unstructured":"Braskie MN, et al. Relationship of striatal dopamine synthesis capacity to age and cognition. J Neurosci. 2008;28(52):14320\u20138.","journal-title":"J Neurosci"},{"issue":"5798","key":"1359_CR180","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/289537a0","volume":"289","author":"A Cheramy","year":"1981","unstructured":"Cheramy A, Leviel V, Glowinski J. Dendritic release of dopamine in the substantia nigra. Nature. 1981;289(5798):537\u201343.","journal-title":"Nature"},{"issue":"4","key":"1359_CR181","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/j.1471-4159.1989.tb01863.x","volume":"52","author":"H Nissbrandt","year":"1989","unstructured":"Nissbrandt H, et al. Synthesis and release of dopamine in rat brain: comparison between substantia nigra pars compacta, pars reticulata, and striatum. J Neurochem. 1989;52(4):1170\u201382.","journal-title":"J Neurochem"},{"issue":"S7","key":"1359_CR182","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1002\/mds.10578","volume":"18","author":"GR Uhl","year":"2003","unstructured":"Uhl GR. Dopamine transporter: basic science and human variation of a key molecule for dopaminergic function, locomotion, and parkinsonism. Mov Disord. 2003;18(S7):S71\u201380.","journal-title":"Mov Disord"},{"issue":"1","key":"1359_CR183","doi-asserted-by":"publisher","first-page":"751","DOI":"10.3390\/ijms24010751","volume":"24","author":"R Camedda","year":"2023","unstructured":"Camedda R, Bonomi CG, Di Donna MG, Chiaravalloti A. Functional correlates of striatal dopamine transporter cerebrospinal fluid levels in Alzheimer\u2019s disease: a preliminary 18F-FDG PET\/CT study. Int J Mol Sci. 2023;24(1):751.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1359_CR184","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41422-023-00906-z","volume":"34","author":"Y Wang","year":"2024","unstructured":"Wang Y, et al. Transport and inhibition mechanism for VMAT2-mediated synaptic vesicle loading of monoamines. Cell Res. 2024;34(1):47\u201357.","journal-title":"Cell Res"},{"issue":"1","key":"1359_CR185","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.cpet.2010.02.001","volume":"5","author":"FF Hefti","year":"2010","unstructured":"Hefti FF, et al. (18)F-AV-133: a selective VMAT2-binding radiopharmaceutical for PET imaging of dopaminergic neurons. PET Clin. 2010;5(1):75\u201382.","journal-title":"PET Clin"},{"issue":"7","key":"1359_CR186","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1001\/archneurol.2011.142","volume":"68","author":"VL Villemagne","year":"2011","unstructured":"Villemagne VL, et al. In vivo assessment of vesicular monoamine transporter type 2 in dementia with Lewy bodies and Alzheimer disease. Arch Neurol. 2011;68(7):905\u201312.","journal-title":"Arch Neurol"},{"key":"1359_CR187","doi-asserted-by":"publisher","first-page":"102012","DOI":"10.1016\/j.arr.2023.102012","volume":"90","author":"D Jeremic","year":"2023","unstructured":"Jeremic D, Navarro-L\u00f3pez JD, Jim\u00e9nez-D\u00edaz L. Efficacy and safety of anti-amyloid-\u03b2 monoclonal antibodies in current Alzheimer\u2019s disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis. Ageing Res Rev. 2023;90:102012.","journal-title":"Ageing Res Rev"},{"issue":"1","key":"1359_CR188","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1370\/afm.3050","volume":"22","author":"MH Ebell","year":"2024","unstructured":"Ebell MH, Barry HC, Baduni K, Grasso G. Clinically important benefits and harms of monoclonal antibodies targeting amyloid for the treatment of Alzheimer disease: a systematic review and meta-analysis. Ann Fam Med. 2024;22(1):50\u201362.","journal-title":"Ann Fam Med"},{"issue":"4","key":"1359_CR189","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41573-022-00391-w","volume":"21","author":"E Karran","year":"2022","unstructured":"Karran E, De Strooper B. The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nat Rev Drug Discov. 2022;21(4):306\u201318.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"1359_CR190","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3390\/biomedicines7040097","volume":"7","author":"KG Yiannopoulou","year":"2019","unstructured":"Yiannopoulou KG, Anastasiou AI, Zachariou V, Pelidou SH. Reasons for failed trials of disease-modifying treatments for Alzheimer disease and their contribution in recent research. Biomedicines. 2019;7(4):97.","journal-title":"Biomedicines"},{"key":"1359_CR191","doi-asserted-by":"publisher","first-page":"111452","DOI":"10.1016\/j.exger.2021.111452","volume":"152","author":"A Gallo","year":"2021","unstructured":"Gallo A, Pillet L-E, Verpillot R. New frontiers in Alzheimer\u2019s disease diagnostic: Monoamines and their derivatives in biological fluids. Exp Gerontol. 2021;152:111452.","journal-title":"Exp Gerontol"},{"issue":"4","key":"1359_CR192","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/j.1582-4934.2008.00313.x","volume":"12","author":"KA Jellinger","year":"2008","unstructured":"Jellinger KA, Janetzky B, Attems J, Kienzl E. Biomarkers for early diagnosis of Alzheimer disease: \u2018ALZheimer ASsociated gene\u2019\u2013a new blood biomarker? J Cell Mol Med. 2008;12(4):1094\u2013117.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"1359_CR193","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40035-022-00296-z","volume":"11","author":"TO Klyucherev","year":"2022","unstructured":"Klyucherev TO, et al. Advances in the development of new biomarkers for Alzheimer\u2019s disease. Transl Neurodegener. 2022;11(1):25.","journal-title":"Transl Neurodegener"},{"issue":"3","key":"1359_CR194","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/jnc.15615","volume":"164","author":"BJ Lopresti","year":"2023","unstructured":"Lopresti BJ, et al. Beyond monoamines: I. Novel targets and radiotracers for Positron emission tomography imaging in psychiatric disorders. J Neurochem. 2023;164(3):364\u2013400.","journal-title":"J Neurochem"},{"issue":"1","key":"1359_CR195","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13024-019-0325-5","volume":"14","author":"F M\u00e1rquez","year":"2019","unstructured":"M\u00e1rquez F, Yassa MA. Neuroimaging biomarkers for Alzheimer\u2019s disease. Mol Neurodegener. 2019;14(1):21.","journal-title":"Mol Neurodegener"},{"issue":"612","key":"1359_CR196","doi-asserted-by":"publisher","first-page":"eabj2511","DOI":"10.1126\/scitranslmed.abj2511","volume":"13","author":"HIL Jacobs","year":"2021","unstructured":"Jacobs HIL, et al. In vivo and neuropathology data support locus coeruleus integrity as indicator of Alzheimer\u2019s disease pathology and cognitive decline. Sci Transl Med. 2021;13(612):eabj2511.","journal-title":"Sci Transl Med"},{"issue":"12","key":"1359_CR197","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.3390\/genes12121959","volume":"12","author":"R Rabaneda-Bueno","year":"2021","unstructured":"Rabaneda-Bueno R, et al. Advances in genetics and epigenetic alterations in Alzheimer\u2019s disease: a notion for therapeutic treatment. Genes (Basel). 2021;12(12):1959.","journal-title":"Genes (Basel)"},{"issue":"4","key":"1359_CR198","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1212\/WNL.0000000000207193","volume":"101","author":"D Alcolea","year":"2023","unstructured":"Alcolea D, et al. Blood biomarkers in neurodegenerative diseases: implications for the clinical neurologist. Neurology. 2023;101(4):172\u201380.","journal-title":"Neurology"},{"key":"1359_CR199","doi-asserted-by":"publisher","first-page":"148812","DOI":"10.1016\/j.brainres.2024.148812","volume":"1830","author":"MM Grigoli","year":"2024","unstructured":"Grigoli MM, Pelegrini LN, Whelan R, Cominetti MR. Present and future of blood-based biomarkers of Alzheimer\u2019s disease: beyond the classics. Brain Res. 2024;1830:148812.","journal-title":"Brain Res"},{"issue":"3","key":"1359_CR200","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):280\u201392.","journal-title":"Alzheimers Dement"},{"key":"1359_CR201","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.pharmthera.2014.07.001","volume":"145","author":"C Sanchez","year":"2015","unstructured":"Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther. 2015;145:43\u201357.","journal-title":"Pharmacol Ther"},{"issue":"5","key":"1359_CR202","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1017\/S146114570800967X","volume":"12","author":"JB O'Sullivan","year":"2009","unstructured":"O\u2019Sullivan JB, et al. Noradrenaline reuptake inhibitors limit neuroinflammation in rat cortex following a systemic inflammatory challenge: implications for depression and neurodegeneration. Int J Neuropsychopharmacol. 2009;12(5):687\u201399.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"1359_CR203","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/glia.23885","volume":"69","author":"M Gonz\u00e1lez-Prieto","year":"2021","unstructured":"Gonz\u00e1lez-Prieto M, et al. Microglial CX3CR1 production increases in Alzheimer\u2019s disease and is regulated by noradrenaline. Glia. 2021;69(1):73\u201390.","journal-title":"Glia"},{"key":"1359_CR204","doi-asserted-by":"publisher","first-page":"8628","DOI":"10.1007\/s12035-019-01695-6","volume":"56","author":"IL Guti\u00e9rrez","year":"2019","unstructured":"Guti\u00e9rrez IL, et al. Reboxetine treatment reduces neuroinflammation and neurodegeneration in the 5xFAD mouse model of Alzheimer\u2019s disease: role of CCL2. Mol Neurobiol. 2019;56:8628\u201342.","journal-title":"Mol Neurobiol"},{"issue":"6","key":"1359_CR205","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1093\/brain\/awab452","volume":"145","author":"AI Levey","year":"2022","unstructured":"Levey AI, et al. A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment. Brain. 2022;145(6):1924\u201338.","journal-title":"Brain"},{"issue":"13","key":"1359_CR206","doi-asserted-by":"publisher","first-page":"6058","DOI":"10.1073\/pnas.0909586107","volume":"107","author":"MT Heneka","year":"2010","unstructured":"Heneka MT, et al. Locus ceruleus controls Alzheimer\u2019s disease pathology by modulating microglial functions through norepinephrine. Proc Natl Acad Sci. 2010;107(13):6058\u201363.","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"1359_CR207","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1046\/j.1471-4159.1998.70062468.x","volume":"70","author":"SA Thomas","year":"1998","unstructured":"Thomas SA, Marck BT, Palmiter RD, Matsumoto AM. Restoration of norepinephrine and reversal of phenotypes in mice lacking dopamine \u03b2-hydroxylase. J Neurochem. 1998;70(6):2468\u201376.","journal-title":"J Neurochem"},{"key":"1359_CR208","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.brainres.2017.12.028","volume":"1702","author":"D Braun","year":"2019","unstructured":"Braun D, Feinstein DL. The locus coeruleus neuroprotective drug vindeburnol normalizes behavior in the 5xFAD transgenic mouse model of Alzheimer\u2019s disease. Brain Res. 2019;1702:29\u201337.","journal-title":"Brain Res"},{"issue":"8","key":"1359_CR209","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.4088\/JCP.v67n0801","volume":"67","author":"CA Merrill","year":"2006","unstructured":"Merrill CA, et al. Vagus nerve stimulation in patients with Alzheimer\u2019s disease: additional follow-up results of a pilot study through 1 year. J Clin Psychiatry. 2006;67(8):1171\u20138.","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"1359_CR210","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1093\/brain\/awx232","volume":"140","author":"JM Rorabaugh","year":"2017","unstructured":"Rorabaugh JM, et al. Chemogenetic locus coeruleus activation restores reversal learning in a rat model of Alzheimer\u2019s disease. Brain. 2017;140(11):3023\u201338.","journal-title":"Brain"},{"issue":"2\u20133","key":"1359_CR211","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.neuropharm.2010.09.002","volume":"60","author":"G Scullion","year":"2011","unstructured":"Scullion G, et al. Chronic treatment with the \u03b12-adrenoceptor antagonist fluparoxan prevents age-related deficits in spatial working memory in APP\u00d7 PS1 transgenic mice without altering \u03b2-amyloid plaque load or astrocytosis. Neuropharmacology. 2011;60(2\u20133):223\u201334.","journal-title":"Neuropharmacology"},{"issue":"11","key":"1359_CR212","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1172\/JCI31547","volume":"117","author":"J Wang","year":"2007","unstructured":"Wang J, et al. Valsartan lowers brain \u03b2-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Investig. 2007;117(11):3393\u2013402.","journal-title":"J Clin Investig"},{"issue":"4","key":"1359_CR213","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.3233\/JAD-2012-120904","volume":"33","author":"J Wang","year":"2013","unstructured":"Wang J, et al. Investigation of nebivolol as a novel therapeutic agent for the treatment of Alzheimer\u2019s disease. J Alzheimers Dis. 2013;33(4):1147\u201356.","journal-title":"J Alzheimers Dis"},{"issue":"11","key":"1359_CR214","doi-asserted-by":"publisher","first-page":"6143","DOI":"10.3390\/ijms23116143","volume":"23","author":"IL Guti\u00e9rrez","year":"2022","unstructured":"Guti\u00e9rrez IL, et al. Noradrenaline in Alzheimer\u2019s disease: a new potential therapeutic target. Int J Mol Sci. 2022;23(11):6143.","journal-title":"Int J Mol Sci"}],"container-title":["GeroScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-024-01359-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11357-024-01359-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-024-01359-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T14:08:38Z","timestamp":1741010918000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11357-024-01359-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":214,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["1359"],"URL":"https:\/\/doi.org\/10.1007\/s11357-024-01359-x","relation":{},"ISSN":["2509-2723"],"issn-type":[{"value":"2509-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]},"assertion":[{"value":"22 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Q.W. serves on the Board of Scientific Advisory for Terran Biosciences, Inc. Q.W. and K.J. are co-founders of BioQure, LLC. F.D. is an associate editor of Geroscience. The other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}